中山醫學大學機構典藏 CSMUIR:Item 310902500/24847
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7417014      在线人数 : 43
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24847


    题名: Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
    作者: Yen, FS;Yang, YC;Hwu, CM;Wei, JCC;Huang, YH;Hou, MC;Hsu, CC
    关键词: nonalcoholic fatty liver disease;cirrhosis;hepatic decompensation;hepatic failure;all-cause mortality;liver-related death
    日期: 2020
    上传时间: 2022-08-09T08:08:57Z (UTC)
    出版者: WILEY
    ISSN: 1478-3223
    摘要: Background & Aims Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short term with moderate sample size, no liver-related long-term outcomes could be noted. Methods This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality between TZD users and nonusers. The Kaplan-Meier method was used to compare the cumulative incidence of these main outcomes. Results The incidence rates of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality during follow-up were 0.77 vs 1.95, 1.43 vs 1.75, 0.36 vs 0.70, and 4.89 vs 3.78 per 1000 person-years between TZD users and nonusers. The adjusted hazard ratios of cirrhosis, hepatic decompensation, hepatic failure and all-cause mortality were 0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 (95% CI: 0.18-1.17) and 1.18 (95% CI: 0.87-1.61) respectively. Conclusions Our study demonstrated that TZD use could significantly lower the risk of cirrhosis. In clinical settings, TZD use might be able to improve liver-related long-term outcomes.
    URI: http://dx.doi.org/10.1111/liv.14385
    https://www.webofscience.com/wos/woscc/full-record/WOS:000512129200001
    https://ir.csmu.edu.tw:8080/handle/310902500/24847
    關聯: LIVER INTERNATIONAL ,2020 ,v40 ,issue 5 ,p1089-1097
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML188检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈